ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012
Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Dopamine in Sports: A Narrative Review on the Genetic and Epigenetic Factors Shaping Personality and Athletic Performance.International journal of molecular sciences · 2024Review
- Low levels of Methyl-CpG binding protein 2 are accompanied by an increased vulnerability to the negative outcomes of stress exposure during childhood in healthy women.Translational psychiatry · 2022Article
- Plasma membrane and brain dysfunction of the old: Do we age from our membranes?Frontiers in cell and developmental biology · 2022Review
- Article
- Regulation of neural differentiation, synaptic scaling and animal behavior by MeCP2 phophorylation.Neurobiology of learning and memory · 2019Article
- MeCP2 Expression in a Rat Model of Risky Decision Making.Neuroscience · 2018Article
- Regulation and function of MeCP2 Ser421 phosphorylation in U50488-induced conditioned place aversion in mice.Psychopharmacology · 2017Article
- Rett syndrome - biological pathways leading from MECP2 to disorder phenotypes.Orphanet journal of rare diseases · 2016Review
- Review
- Regulation and function of stimulus-induced phosphorylation of MeCP2.Frontiers in biology · 2014Article
- Epigenetics and the regulation of stress vulnerability and resilience.Neuroscience · 2014Review
- MeCP2 phosphorylation limits psychostimulant-induced behavioral and neuronal plasticity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- DNA methylation and its basic function.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Review
- Phosphorylation of MeCP2 at Ser421 contributes to chronic antidepressant action.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012Article
- The molecular basis of cognitive deficits in pervasive developmental disorders.Learning & memory (Cold Spring Harbor, N.Y.) · 2012Review
- Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings.Journal of neurodevelopmental disorders · 2012Article
- The many faces of MeCP2.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Systemic administration of amphetamine (AMPH) induces phosphorylation of MeCP2 at Ser421 (pMeCP2) in select populations of neurons in the mesolimbocortical brain regions. Because AMPH simultaneously activates multiple monoamine neurotransmitter systems, here we examined the ability of dopamine (DA), serotonin (5-HT), and norepinephrine (NE) to induce pMeCP2. Selective blockade of the DA transporter (DAT) or the 5-HT transporter (SERT), but not the NE transporter (NET), was sufficient to induce pMeCP2 in the CNS. DAT blockade induced pMeCP2 in the prelimbic cortex (PLC) and nucleus accumbens (NAc), whereas SERT blockade induced pMeCP2 only in the NAc. Administration of selective DA and 5-HT receptor agonists was also sufficient to induce pMeCP2; however, the specific combination of DA and 5-HT receptors activated determined the regional- and cell-type specificity of pMeCP2 induction. The D(1)-class DA receptor agonist SKF81297 induced pMeCP2 widely; however, coadministration of the D(2)-class agonist quinpirole restricted the induction of pMeCP2 to GABAergic interneurons of the NAc. Intra-striatal injection of the adenylate cyclase activator forskolin was sufficient to induce pMeCP2 in medium-spiny neurons, suggesting that the combinatorial regulation of cAMP by different classes of DA and 5-HT receptors may contribute to the cell-type specificity of pMeCP2 induction. Consistent with the regulation of pMeCP2 by multiple monoamine neurotransmitters, genetic disruption of any single monoamine transporter in DAT-, SERT-, and NET-knockout mice failed to eliminate AMPH-induced pMeCP2 in the NAc. Together, these studies indicate that combinatorial signaling through DA and 5-HT receptors can regulate the brain region- and cell-type specific pMeCP2 in the CNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.